Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report
Title: | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report |
Authors: | Umemura, Machiko Browse this author | Suda, Goki Browse this author →KAKEN DB | Tsukamoto, Shihori Browse this author | Ebata, Ko Browse this author | Takahash, Shinjiro Browse this author | Sasaki, Takashi Browse this author | Nakajima, Sae Browse this author | Hirata, Koji Browse this author | Ozasa, Mariko Browse this author | Takano, Masatoshi Browse this author | Katagiri, Masaki Browse this author | Sakamoto, Naoya Browse this author |
Keywords: | Glecaprevir | Hepatitis C virus | Pibrentasvir | Direct-acting antiviral | hepatitis C flare |
Issue Date: | 27-Apr-2021 |
Publisher: | BioMed Central |
Journal Title: | BMC infectious diseases |
Volume: | 21 |
Issue: | 1 |
Start Page: | 389 |
Publisher DOI: | 10.1186/s12879-021-06091-x |
Abstract: | Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP. |
Type: | article |
URI: | http://hdl.handle.net/2115/82145 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|